| scholarly article | Q13442814 |
| P50 | author | Stefania Bettelli | Q51702921 |
| Antonino Maiorana | Q51702925 | ||
| Enrico Tagliafico | Q53072094 | ||
| Pierfranco Conte | Q56798835 | ||
| Antonio Frassoldati | Q56826846 | ||
| Daniele Generali | Q56946462 | ||
| A Musolino | Q57076640 | ||
| Maria Vittoria Dieci | Q57656975 | ||
| Valentina Guarneri | Q58283362 | ||
| P2093 | author name string | Samanta Sarti | |
| Silvio Bicciato | |||
| Rocco Crescenzo | |||
| Catherine Ellis | |||
| Guido Ficarra | |||
| Giancarlo Bisagni | |||
| Katia Cagossi | |||
| P2860 | cites work | A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 |
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 | ||
| Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study | Q33688726 | ||
| PREDA: an R-package to identify regional variations in genomic data. | Q33956537 | ||
| Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. | Q34275072 | ||
| Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa | Q34296114 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). | Q36649356 | ||
| Structural comparisons of class I phosphoinositide 3-kinases | Q37218678 | ||
| A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets | Q37318482 | ||
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer | Q37380424 | ||
| Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes | Q37457262 | ||
| p95HER2 and breast cancer | Q37846003 | ||
| Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. | Q37877173 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients | Q39674995 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. | Q41735415 | ||
| Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. | Q44723581 | ||
| Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
| Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff | Q46058629 | ||
| A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy | Q46120275 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. | Q52874022 | ||
| The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer | Q81557497 | ||
| P433 | issue | 9 | |
| P921 | main subject | trastuzumab | Q412616 |
| biomarker | Q864574 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1001-1010 | |
| P577 | publication date | 2015-08-05 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | |
| P478 | volume | 20 |
| Q95492561 | Q95492561 |
| Q92121461 | A meta-analysis of multiple matched aCGH/expression cancer datasets reveals regulatory relationships and pathway enrichment of potential oncogenes |
| Q88639406 | Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer |
| Q59329859 | Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings |
| Q91693727 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study |
| Q91637188 | Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q33829405 | ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression |
| Q54957080 | Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. |
| Q50083199 | Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies |
| Q39034850 | HER2-positive breast cancer |
| Q38648765 | HER2-positive breast cancer is lost in translation: time for patient-centered research |
| Q51663342 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. |
| Q41149668 | Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. |
| Q64123416 | Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| Q42497114 | Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial |
| Q57107866 | Is there a role for immunotherapy in HER2-positive breast cancer? |
| Q36653537 | Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes. |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q38752466 | Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. |
| Q47782850 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). |
| Q55428234 | Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. |
| Q38782016 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer |
| Q48205560 | Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies |
| Q90749764 | PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer |
| Q64106572 | PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial |
| Q39767744 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. |
| Q54187441 | PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. |
| Q38786102 | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge |
| Q90226704 | Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives |
| Q51016839 | Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. |
| Q37362747 | TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting |